Navigation Links
DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
Date:11/15/2012

armacokinetics and anti-tumor activity of VAL-083 in patients with histologically confirmed initial diagnosis of primary WHO Grade IV malignant glioma (GBM), now recurrent.  Patients with prior low-grade glioma or anaplastic glioma are eligible, if histologic assessment demonstrates transformation to GBM.  Patients with secondary brain tumors due to CNS metastases are also eligible for the study.

GBM patients must have been previously treated for GBM with surgery and/or radiation, if appropriate, and must have failed both Bevacizumab (Avastin®) and temozolomide (Temodar®), unless either or both are contra-indicated. 

Response to therapy and disease progression will be evaluated by MRI prior to each treatment cycle.  An initial phase of the study will involve dose escalation cohorts until a maximum tolerated dose (MTD) is established in the context of modern care.  Once the modernized dosing regimen has been established, additional patients will be enrolled at the MTD (or other selected optimum dosing regimen).

DelMar Pharma is conducting the study under the direction of Dr. Howard Burris at the Sarah Cannon Research Institute in Nashville, Tennessee with a second center in Sarasota, Florida. 

Please refer to clinicaltrials.gov identifier NCT01478178 for further details on this clinical trial.

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment o
'/>"/>

SOURCE Del Mar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auspex Pharmaceuticals Receives U.S. Patent on Novel JAK Inhibitor SD-900
2. Access Pharmaceuticals To Host Third Quarter Investor Call on Wednesday, November 28th
3. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
4. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
5. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
6. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
7. Frost & Sullivan: Lack of Proper Price Regulation for Pharmaceuticals
8. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
9. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
10. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
11. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
(Date:8/28/2015)... 2015 The global mHealth ... billion by 2020, growing at a CAGR of 47.6% ... by Grand View Research, Inc. Monitoring services is expected ... 2014 to 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... rising incidences of chronic diseases such as cancer, heart ...
(Date:8/27/2015)... , Aug. 27, 2015 DURECT Corporation (Nasdaq: ... to present at three upcoming healthcare conferences.  ... CEO, will present at the Rodman & Renshaw Investment ... time. The conference is being held at the St. ... . A live audio webcast of the presentation will ...
Breaking Medicine Technology:Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5DURECT to Participate in Upcoming Healthcare Conferences 2
... symptoms of SLE,disease at 52 Weeks and ... weeks-, ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ ... presentation of Phase 2,trial data demonstrating that ... clinical,measures, was well tolerated and improved quality ...
... June 13, 2007 /PRNewswire/ -- Two studies presented,today ... at peak,plasma levels, nor did it impair middle-of-the-night ... from chronic,insomnia. The results of the studies were ... Professional Sleep Societies,(APSS). , "These data are important ...
Cached Medicine Technology:Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 2Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 4Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 5
(Date:8/29/2015)... ... August 30, 2015 , ... On September 30, 2015, the Career ... the 10 regionally accredited Maricopa Community Colleges , will be hosting a Job ... pursuing employment information and opportunities. , The Expo has expanded to much more than ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from ... previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are ...
(Date:8/28/2015)... ... 28, 2015 , ... Joining a growing number of hospitals ... management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA provides ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of ... for the second year to the Adams County Fairgrounds in Mendon, IL on May ... raise money to support music education in the underfunded school districts of Mendon and ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... contain possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). ... Standards and Technology and the Environmental Protection Agency of ... yet clear how dangerous these PBDEs are, though some ... structure is strikingly similar to that of PCBs, which ...
... are suffering from mental illness after serving in war-torn ... or longer for treatment// from the National Health Service ... by British Ministry of Defence (MoD) showed 2,123 servicemen ... after returning from Iraq since 2003. More than 320 ...
... has set up a facility in Chennai, the state ... ,Called Poison Control Training and Research Centre, ... It can handle emergency situations like mass poisoning. It ... services and counseling. An intensive care unit, a library, ...
... the hospitals run by NHS trusts, more and more people ... According to the Daily Telegraph, the bed occupancy rates in ... ,Norman Lamb, the health spokesman of the Liberal ... an uphill task to keep patients clean and isolate them. ...
... a tool to help hospitals prepare for disasters ... Electronic Mass Casualty Assessment & Planning Scenarios (EMCAPS) ... as a flu epidemic, bioterrorist attack, flood or ... of victims, wind direction, available medical resources, bacterial ...
... posed by mercury contaminated fish are enormous and especially ... careful about how much// and which fish they eat ... a special issue of the international science journal Ambio. ... Mercury as a Global Pollutant last August in Madison, ...
Cached Medicine News:Health News:Methylmercury in Marine Fish Pose Health Risks to Pregnant Women and Elderly Men 2Health News:Methylmercury in Marine Fish Pose Health Risks to Pregnant Women and Elderly Men 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: